knowledge -WSS

knowledge

author：comprehensive 2025-10-02 08:24:17 - browse：8

President Joe Biden talks in the Roosevelt Room of the White House, in front of a painting of Theodore Roosevelt on a horse back — politics coverage from STAT — President Biden MANDEL NGAN/AFP via Getty Images

WASHINGTON — The White House is throwing its support behind a controversial authority that allows the government to undermine patent rights for certain high-priced medicines. It’s an early step that could have major ramifications for the American pharmaceutical industry, depending on whether and how federal officials actually use the authority.

The administration issued a framework for the National Institutes of Health to more broadly use so-called “march-in rights” — a policy that allows it to invalidate patent rights from drugmakers whose products rely on federally funded research. The framework lays out when the agency might assert this authority, and endorse using a drug’s price in that determination.

“We’ll make clear that when drug companies won’t sell taxpayer funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House National Economic Advisor Lael Brainard told reporters. “These authorities are in existing laws, the last administration just didn’t want to allow them to be used in this way.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Cell therapy fails to slow type 1 diabetes, but safety is established

WSS

Close Medicare's dangerous gaps in addiction treatment coverage

Pennsylvania man bitten on the head by bear during attack in his garage

Dogs on Prozac: What pet anti

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast

Failure, not just success, should guide future doctors

Why does health care cost so much? A reading guide

knowledge

knowledge

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Medical bills so high, Medicare adding extra digits to claim forms

Medical leaders decry Supreme Court decision on affirmative action

Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?

Dobbs anniversary: the lost opportunity of abortion as health care

Cholera vaccine supply gets boost as demand surges globally

Virginia high school admissions case could be legal follow

Sage considers ways to reduce costs following FDA rejection

After affirmative action ruling, medical educators look to 'holistic review'

Q&A: Jennifer Adair on making gene therapy available globally

explore

After traumatic brain injury, life support decisions can use more time

Sage considers ways to reduce costs following FDA rejection

Doctors push to include dialysis machines in emergency stockpile

MultiPlan and major insurers sued for alleged medical price

Key Senate committee drafts bipartisan bill to stem drug shortages

Cue Health's Covid

focus

hotspot

Wikipedia

leisure time